Lamotrigine Should Be Discontinued in This Patient Developing Hypomanic Symptoms
No, lamotrigine is not providing sufficient benefit to emotional reactivity to justify continuing it when a patient on aripiprazole 15 mg daily is developing hypomanic symptoms—in fact, lamotrigine may be contributing to the problem and should be discontinued.
The Core Issue: Lamotrigine's Lack of Antimanic Efficacy
Lamotrigine has no demonstrated efficacy for acute mania or hypomania 1. The guidelines are explicit: lamotrigine is FDA-approved for maintenance therapy in adults to prevent mood episodes, but controlled studies show it is ineffective for treating acute manic symptoms 1. When hypomanic symptoms emerge, you need an agent with antimanic properties—which lamotrigine fundamentally lacks.
The Risk of Lamotrigine-Induced Mania
More concerning, lamotrigine can actually induce or worsen manic episodes 2, 3. Recent evidence identifies specific vulnerable populations:
- Patients with Bipolar I disorder (like yours, given they're on aripiprazole)
- Those with manic predominant polarity
- Patients with a history of antidepressant-induced switches
The mechanism relates to lamotrigine's antidepressant properties through decreased glutamate release, combined with its complete absence of antimanic effects 2. In documented cases, manic symptoms resolved within 1-2 weeks after lamotrigine discontinuation 2, 3.
What Actually Works for Hypomania
The evidence is clear on effective antimanic agents 1:
FDA-approved for acute mania:
- Lithium (down to age 12)
- Aripiprazole (already being used)
- Valproate
- Olanzapine
- Risperidone
- Quetiapine
- Ziprasidone
Your patient is already on aripiprazole 15 mg daily, which is FDA-approved for acute mania 4. The FDA label shows aripiprazole doses of 10-30 mg/day are effective, with no clear advantage of higher doses over 10-15 mg 4.
The Clinical Algorithm
Immediate action:
- Discontinue lamotrigine to eliminate a potential contributor to hypomanic symptoms
- Optimize aripiprazole dosing - consider increasing from 15 mg to 20-30 mg daily if symptoms persist, as the therapeutic range extends to 30 mg 4
- Add lithium or valproate if aripiprazole optimization alone is insufficient 1
Avoid unnecessary polypharmacy: The guidelines explicitly warn against this 1. Continuing an ineffective agent (lamotrigine) while adding or increasing other medications violates this principle.
The "Emotional Reactivity" Argument Doesn't Hold
While lamotrigine may have helped with depressive symptoms or mood stability previously, this benefit is irrelevant when acute hypomanic symptoms emerge. The priority hierarchy is:
- Control the acute mood episode (hypomania) with antimanic agents
- Prevent morbidity from escalating mania
- Consider maintenance therapy only after acute stabilization
Lamotrigine's role is in maintenance therapy to prevent depressive episodes 1, 5, not managing acute hypomania. The systematic review by Geddes et al. confirms lamotrigine is indicated for prophylaxis of bipolar disorder with predominantly depressive episodes, with no grounds for use in manic or mixed states 5.
Common Pitfall to Avoid
Don't fall into the trap of maintaining lamotrigine because "it might be helping something." When a patient develops breakthrough hypomanic symptoms, this represents treatment failure of the current regimen. The combination of aripiprazole (which has antimanic properties) plus lamotrigine (which has none and may worsen mania) is illogical when hypomania emerges.
The evidence-based approach: discontinue lamotrigine, optimize aripiprazole dosing (potentially increase to 20-30 mg), and add lithium or valproate if needed 1, 4.